These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32395382)

  • 61. Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy.
    Teixidó C; Karachaliou N; González-Cao M; Morales-Espinosa D; Rosell R
    Cancer Biol Med; 2015 Sep; 12(3):259. PubMed ID: 26487971
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Factors related with pathological complete response of neoadjuvant chemotherapy in primary breast cancer].
    Cheng YJ; Ye JM; Xu L; Zhao JX; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2013 Apr; 51(4):339-43. PubMed ID: 23895756
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Feasibility of predicting pathological evaluation by ultrasonic evaluation in initial stage of neoadjuvant chemotherapy for primary breast cancer].
    Qi M; Li JF; Xie YT; Lu AP; Liu YQ; Lin BY; Ouyang T
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(8):511-4. PubMed ID: 20367959
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Erratum: Expression of Tim-3 in breast cancer tissue promotes tumor progression.
    Cheng S; Han F; Xu Y; Qu T; Ju Y
    Int J Clin Exp Pathol; 2021; 14(7):855. PubMed ID: 34367417
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer.
    Cuello-López J; Fidalgo-Zapata A; López-Agudelo L; Vásquez-Trespalacios E
    PLoS One; 2018; 13(11):e0207224. PubMed ID: 30427884
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Erratum: Author's Name Correction for "From Radical to Partial Nephrectomy in the Setting of Solitary Functioning Kidney: Neoadjuvant Treatment of Renal Cell Carcinoma".
    Watson DD; Farha NG; Kallail KJ; Dakhil S; Farha AJ
    Rev Urol; 2020; 22(4):186. PubMed ID: 33927579
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Radiological and Pathological Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Brief Literature Review.
    Parekh T; Dodwell D; Sharma N; Shaaban AM
    Pathobiology; 2015 Sep; 82(3-4):124-32. PubMed ID: 26330353
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
    Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
    Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MicroRNA-143 is Associated With Pathological Complete Response and Regulates Multiple Signaling Proteins in Breast Cancer.
    García-Vázquez R; Marchat LA; Ruíz-García E; Astudillo-de la Vega H; Meneses-García A; Arce-Salinas C; Bargallo-Rocha E; Carlos-Reyes Á; López-González JS; Pérez-Plasencia C; Ramos-Payán R; Aguilar-Medina M; López-Camarillo C
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819827309. PubMed ID: 30755102
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: correlation with molecular phenotype].
    Blanco Sánchez A; Yébenes L; Berjón A; Hardisson D
    Rev Esp Patol; 2021; 54(1):8-16. PubMed ID: 33455698
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Cabrera-Galeana P; Soto-Perez-de-Celis E; Reynoso-Noveron N; Villarreal-Garza C; Lara-Medina F; Alvarado-Miranda A; Espinosa-Fernandez JR; Esparza-Arias N; Mohar A; Bargallo-Rocha JE
    Oncologist; 2020 Dec; 25(12):1023-1031. PubMed ID: 32275801
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
    Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
    Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Erratum: The Basic Facts of Korean Breast Cancer in 2011: Results of a Nationwide Survey and Breast Cancer Registry Database.
    Kim Z; Min SY; Yoon CS; Lee HJ; Lee JS; Youn HJ; Park HK; Noh DY; Hur MH;
    J Breast Cancer; 2015 Sep; 18(3):301. PubMed ID: 26472983
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
    Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
    Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Texture analysis based on contrast-enhanced MRI can predict treatment response to neoadjuvant chemotherapy of breast cancer].
    Sun SH; Zhou CW; Zhao LY; Zhang RZ; Ouyang H
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):344-349. PubMed ID: 28535650
    [No Abstract]   [Full Text] [Related]  

  • 76. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer.
    Qin Q; Gao F; Jiang W; Tan Q; Mo Q; Wei C
    Chin Med J (Engl); 2014; 127(18):3272-7. PubMed ID: 25266526
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Erratum: Clinicopathologic Characteristics of Breast Cancer Stem Cells Identified on the Basis of Aldehyde Dehydrogenase 1 Expression.
    Kim YS; Jung MJ; Ryu DW; Lee CH
    J Breast Cancer; 2016 Sep; 19(3):340. PubMed ID: 27721888
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Koolen BB; Wessels LF; Rodenhuis S; Wesseling J
    Breast Cancer Res Treat; 2013 Jul; 140(1):63-71. PubMed ID: 23828499
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Erratum: Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy [Erratum].
    Cancer Manag Res; 2016; 8():83. PubMed ID: 27390532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.